Earnings Call Summary | Theravance Biopharma(TBPH.US) Q4 2023 Earnings Conference
Earnings Call Summary | Theravance Biopharma(TBPH.US) Q4 2023 Earnings Conference
The following is a summary of the Theravance Biopharma, Inc. (TBPH) Q4 2023 Earnings Call Transcript:
以下是Theravance Biopharma, Inc.（TBPH）2023年第四季度業績電話會議記錄摘要：
Financial Performance:
財務業績：
YUPELRI's net sales growth for the full year of 2023 was 9%, achieving $221 million in sales, with Q4 net sales reaching $60.6 million.
Theravance achieved a record high collaboration revenue of $17.4 million, reflecting a 19% YoY increase.
Theravance reported a GAAP loss of $8.5 million due to an inflated income tax expense, despite a non-GAAP profit of $1.4 million for the quarter.
The firm repurchased approximately $30 million of shares during Q4, reducing the share count by 3 million for the quarter and by 31 million from the start of the program.
Theravance ended the quarter with $102 million in cash and about 48 million shares outstanding.
Theravance increased its Q4 and annual 2023 YUPELRI net sales to $61 million and $221 million respectively.
YUPELRI在2023年全年的淨銷售額增長了9％，實現了2.21億美元的銷售額，第四季度的淨銷售額達到6,060萬美元。
Theravance實現了創紀錄的1740萬美元的合作收入，同比增長了19％。
Theravance報告稱，儘管本季度非公認會計准則利潤爲140萬美元，但由於所得稅支出膨脹，GAAP虧損爲850萬美元。
該公司在第四季度回購了約3000萬股股票，使該季度的股票數量減少了300萬股，自該計劃開始以來減少了3,100萬股。
Theravance在本季度末擁有1.02億美元的現金和約4,800萬股已發行股票。
Theravance將其第四季度和2023年年度YUPELRI的淨銷售額分別提高至6100萬美元和2.21億美元。
Business Progress:
業務進展：
Theravance aims for significant adoption of the ampreloxetine therapy among targeted patients, which is progressing in their CYPRESS study.
AI tools have identified additional qualified sites for their research, improving the scope of their CYPRESS study.
Theravance is an early adopter of telehealth, incorporating it into its research strategy.
Significant progress made in activating research sites, particularly in Europe but also the U.S.
YUPELRI's share of the long-acting NEB market in hospital segment is 16.6% in Q4.
Retail prescriptions grew 7% sequentially during the quarter with new product starts also growing a sequential 7% in Q4.
Theravance Biopharma Inc. achieved non-GAAP profitability in Q4 2023 and successfully executed a $325 million capital return program.
The company anticipates generating net cash before the CYPRESS topline data readout in 2025 due to potential milestones in 2024.
They initiated the ampreloxetine CYPRESS study with approval for orphan drug status and expect the last patient to be enrolled by H2 2024.
They expect to approach break-even on a non-GAAP basis in H2 2024 based on YUPELRI growth and CYPRESS progress.
The firm will launch a virtual investor event in Q2 2024 to discuss the unmet need in MSA patients with symptomatic nOH and the expected benefits of ampreloxetine.
Theravance的目標是在靶向患者中大量採用安普洛西汀療法，他們的CYPRESS研究正在取得進展。
人工智能工具已經爲他們的研究確定了更多合格的研究地點，從而擴大了他們的CYPRESS研究範圍。
Theravance是遠程醫療的早期採用者，已將其納入其研究戰略。
在激活研究場所方面取得了重大進展，特別是在歐洲，還有美國
第四季度，YUPELRI在醫院領域的長效NEB市場的份額爲16.6％。
零售處方在本季度連續增長了7％，第四季度新產品開工量也連續增長了7％。
Theravance Biopharma Inc.在2023年第四季度實現了非公認會計准則盈利能力，併成功執行了3.25億美元的資本回報計劃。
由於2024年可能出現里程碑，該公司預計將在2025年CYPRESS收入數據公佈之前產生淨現金。
他們啓動了安普洛西汀CYPRESS研究，批准了孤兒藥地位，並預計最後一名患者將在2024年下半年入組。
根據YUPELRI的增長和CYPRESS的進展，他們預計將在2024年下半年在非公認會計准則基礎上實現盈虧平衡。
該公司將在2024年第二季度啓動虛擬投資者活動，討論有症狀NoH的MSA患者未得到滿足的需求以及安普洛西汀的預期益處。
More details: Theravance Biopharma IR
更多詳情： Theravance 生物製藥紅外
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。